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Neuron-microglia interactions play a crucial role in maintaining the 
neuroimmune system. The balance of neuroimmune system has emerged 
as an important process in the pathophysiology of depression. However, 
how neuron-microglia interactions contribute to major depressive 
disorders has been poorly understood. Herein, I demonstrated that 
microglia-derived neuronal changes induced antidepressive-like 
behavior by using microglia-specific signal transducer and activator of 
transcription 3 (STAT3) knockout (STAT3fl/fl;LysM-Cre+/-) mice. I 
found that microglia-specific STAT3 knockout mice showed 
antidepressive-like behavior in the forced swim, tail suspension, sucrose 
preference and open field tests. Surprisingly, the secretion of macrophage 
colony-stimulating factor (M-CSF) was increased from neuronal cells 
in the brains of STAT3fl/fl;LysM-Cre+/- mice. Moreover, the 
phosphorylation of antidepressant-targeting mediators and brain-
derived neurotrophic factor (BDNF) expression were increased in the 
brains of STAT3fl/fl;LysM-Cre+/- mice as well as in neuronal cells in 
response to M-CSF stimulation. Collectively, microglial STAT3 regulates 
depression-related behaviors via M-CSF-mediated neuronal activity, 
suggesting that inhibition of microglial STAT3 might be a new 
 2 
therapeutic strategy for depression. 
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Microglia are the resident macrophages of the central nervous system 
(CNS), belonging to the glial system of non-neuronal cells that support 
and protect neuronal functions in the brain and the spinal cord (Lawson 
et al, 1990). Microglia arise during the early embryonic life, accounting 
for 10–20% of the total glial cell population within the CNS 
parenchyma. Regulation of the microglial function plays a pivotal role in 
maintaining the homeostasis of the CNS in both health and disease (Perry 
et al, 2010). 
 
Microglia are immune cells that act as a sentinel to detect the first signs 
of pathogenic invasion or tissue damage in the brain’s sensitive immune 
system (Wake et al, 2013). Under the inflammatory conditions of an 
active immune response, microglia regulate the potential damage to the 
CNS and supports tissue repair and remodeling. Abnormal activation of 
microglia and microglia-induced inflammation are observed in a variety 
of brain pathologies, suggesting that microglia have a direct effect on 




Neuron-microglia interactions play a crucial role in maintaining the 
neuroimmune system (Rogers et al, 2011; Wake et al, 2013; Zhan et al, 
2014). Recent evidence has focused on the imbalance of the 
neuroimmune system in association with psychiatric disorders, such as 
major depression (Couch et al, 2013). Presumably, microglial 
dysfunction causes disturbances in synaptic regulation, resulting in major 
depression. However, the cellular and molecular mechanisms of major 
depression underpinning the bidirectional interplay between neurons and 
microglia remain unclear. 
 
For decades, many studies focused on novel therapeutic approaches for 
major depression (Domino et al, 2008; Goodyer et al, 2007). The 
intracellular signaling pathways of extracellular signal-regulated kinase 
(ERK)1/2, Akt and glycogen synthase kinase-3 beta (GSK3β) have been 
identified as the potent targets for antidepressants (Duman et al, 2016). 
According to postmortem studies, ERK1/2 signaling, which is 
downregulated in the brains of patients with major depression (Dwivedi 
et al, 2005; Dwivedi et al, 2001), has been implicated in antidepressant 
treatment (Duman et al, 2012b; Einat et al, 2003; Tardito et al, 2006). 
While the blockade of the ERK signaling pathway leads to depression-
related behaviors, antidepressant treatments increase ERK 
phosphorylation (Gourley et al, 2007; Hisaoka et al, 2007). Additionally, 
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GSK3β is regarded as a key factor involved in psychiatric diseases 
(Beurel et al, 2015; Chuang et al, 2011; Jope and Roh, 2006). Recent 
studies showed increased GSK3β activity in the cortical regions of 
postmortem brains of suicide victims who had suffered from depression 
(Karege et al, 2007). However, the inactivation of GSK3β using lithium 
or valproate may alleviate unipolar depression (Chen et al, 2000; 
Cipriani et al, 2006; Davis et al, 1996). GSK3β is also negatively 
regulated by phosphatidylinositol 3-kinase (PI3K)-mediated Akt 
activation (Fang et al, 2000). 
 
Despite having a sufficient knowledge of ERK1/2 and Akt/GSK3β 
signaling pathways, the etiological factors leading to major depression 
remain unknown. Recent studies showed that neuroinflammation caused 
by stress-induced activation of microglia leads to depressive-like 
behaviors (Brites and Fernandes, 2015; Steiner et al, 2011; Streit et al, 
2004). In addition to microglial activation, microglial senescence and 
decline can negatively affect neurogenesis, causing major depression 
(Caldeira et al, 2014; Kreisel et al, 2014). These findings suggest the 
importance of microglial activation status in depression. 
 
Signal transducer and activator of transcription 3 (STAT3) is activated 
by various cytokines and growth factors, and plays a major role in 
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causing an inflammatory response by increasing cell activation. STAT3 
also functions as one of the transcription factors for cytokine production 
(El Kasmi et al, 2006), such as soluble intracellular cell adhesion 
molecule-1 (sICAM-1) (Park et al, 2013), interleukin-6 (IL-6) (Mori 
et al, 2011), interleukin-10 (IL-10) (Riley et al, 1999), tumor necrosis 
factor-alpha (TNF-α) (Chabot et al, 1997; Riazi et al, 2008) and 
interleukin-1 beta (IL-1β) (Clausen et al, 2008). Increased these 
cytokines can confer protection to the brain following an acute 
inflammation, yet under conditions of chronic immune activation, 
microglia become a main source of inflammatory cytokines that can 
affect the neuronal function and neurotransmitter system (Felger and 
Lotrich, 2013; Khairova et al, 2009). These cytokines also have been 
identified as mediators for the neuroimmune system of depression (Hodes 
et al, 2015). For example, pathological levels of these cytokines 
contribute to behavioral deficits such as depressive-like behavior (Audet 
and Anisman, 2013; Khairova et al, 2009; Schiepers et al, 2005), 
requiring a more sophisticated manipulation of cytokine levels. Thus, by 
inhibiting STAT3, the level of mediators affecting the inflammatory 
response can be reduced, which has been selected as a therapeutic target 
for psychiatric diseases as well as various inflammatory diseases. 
 
In this study, I hypothesized that STAT3 signaling in microglia affects 
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neuron-microglia interactions via secreted cytokines, resulting in 
synaptic and behavioral changes. To investigate the key factors regulated 
by microglial STAT3 in neuron-microglia interactions, I used microglia-
targeted STAT3-deficient mice and analyzed the molecular mechanisms 
and their behavioral phenotypes. As a result, I revealed that STAT3 
dysfunction in microglia led to antidepressive-like behavior via crosstalk 
between neurons and microglia, suggesting a novel therapeutic avenue 




MATERIALS AND METHODS 
 
Experimental animals and genotyping 
Mice homozygous for the loxP-flanked (floxed) STAT3 gene (STAT3fl/fl) 
were kindly gifted from Dr. S. Akira (Osaka University, Suita, Japan). 
Mice carrying a Cre transgene under the control of the distal LysM 
promoter (LysM-Cre+/+) were purchased from the Jackson Laboratory 
(Bar Harbor, ME, USA). Mice with a STAT3 deletion in myeloid cells 
were generated by crossing mice with the floxed STAT3 allele with mice 
expressing Cre under the control of the LysM promoter. Genomic DNA 
was isolated from tail tips using a NucleoSpin genomic DNA purification 
kit (Macherey-Nagel GmbH & Co., Duren, North Rhine-Westphalia, 
Germany). The polymerase chain reaction (PCR) was performed using 
AccuPowerTM PCR premix (Bioneer, Daejeon, Korea) with the primers, 
which are specific for exons 22 and 23 of STAT3 and Cre transgene, 
according to the manufacturer’s instructions. All experiments were 
performed with male mice aged 8–10 weeks. Experimental animals were 
maintained under specific pathogen-free conditions and 22±1°C with 
a reversed 12-hour light-dark cycle (lights on at 7:00 AM). All 
experimental procedures were reviewed and approved by the 
Institutional Animal Care and Use Committee (IACUC) at the College of 
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Medicine, Seoul National University. 
 
Primary microglia cell culture 
Primary microglia cells were isolated from primary mixed glial cells of 
2-day-old mice. To obtain mixed glial cells, cerebral cortices were 
dissected, carefully stripped of their meninges, and dissociated into a 
single-cell suspension by trituration. Cells were cultured on poly-L-
lysine (Sigma-Aldrich, St Louis, MO, USA)-coated 100mm2 culture dish 
in Dulbecco’s modified Eagle’s medium (DMEM, Hyclone, Logan, UT, 
USA) containing 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin solution (Gibco, Grand Island, NY, USA), and incubated 
at 37°C in 5% CO2. On the third day of culture, cells were vigorously 
washed with pipetting and the media was replaced to remove debris. 
After six days in vitro, cells were transferred to a T-75 flask and 
incubated for 1-3 weeks. Then, the conditioned media were replaced 
with fresh media to achieve complete confluence. To isolate microglia, 
the T-75 flask was rotated (200rpm, 37°C, 5 hours) using a 
temperature-controlled, non-humidified shaker, and then supernatant 
media containing microglia was centrifuged (215×g, 5 minutes). The 
microglial pellet was suspended and seeded onto poly-L-lysine-coated 
60 mm2 cover glass bottom dish (SPL Life Sciences, Pocheon, Korea), and 
incubated at 37°C in 5% CO2. 
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Cell culture and co-culture experiments 
Mouse microglia cell line BV2 and mouse hippocampal neuronal cell line 
HT22 (ATCC, Manassas, VA, USA) were cultured in DMEM containing 
10% FBS and 1% penicillin-streptomycin solution and incubated at 
37°C in 5% CO2. HT22 cells were starved before stimulation for 8 hours 
and then stimulated with M-CSF (40ng/ml, ProSpec, East Brunswick, 
NJ, USA) in a time-dependent manner or 24 hours. Before the co-
culture experiment, BV2 cells were seeded in 6-well dishes at 4×104 
cells/well and transfected with STAT3 siRNAs for 24 hours. The cells 
were washed twice with PBS and then incubated in fresh DMEM 
containing 10% FBS after transfection. Then, the HT22 cells were 
cultured on 0.4μm pore-size Falcon cell culture inserts (Corning 
Incorporated, Durham, NC, USA) at 2×105 cells/well in DMEM 
containing 10% FBS and co-cultured with BV2 cells for 24 hours. To 
confirm the effect of macrophages on neurons, HT22 cells were treated 
with culture medium of RAW264.7 cells with or without STAT3 
inhibition for 24 hours. 
 
siRNA transfection 
BV2 cells and RAW264.7 cells were cultured in the growth condition to 
a density of 2×105 cells in 6-well culture plate. The cells were transfected 
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with the siRNAs using HiperFect transfection reagent (Qiagen, 
Germantown, MD, USA) according to the fast-forward protocol of 
manufacturer’s instructions. STAT3 siRNAs targeting two different 
regions of STAT3 (SI01435287 and SI01435294), and a negative control 
siRNA (1027280) were purchased from Qiagen.  
 
Immunohistochemistry 
Brains of mice were perfused with buffer containing 4% 
paraformaldehyde, fixed for two days in 4% paraformaldehyde at 4°C 
and embedded in paraffin. The paraffin blocks were cut using a 
microtome (4μm, Finesse E +, Thermo Shandon, Runcom, UK). Paraffin 
slices were mounted on the silane-coated micro slides (Muto Pure 
Chemicals, Tokyo, Japan), and then allowed to air dry at room 
temperature in the dark for 24 hours. Before immunostaining, the slides 
were deparaffinized in xylene, dehydrated through graded alcohols, and 
heated in citrate buffer for 10 minutes. Nonspecific binding was blocked 
with 5% normal goat serum (Vector Laboratories, Burlingame, CA, USA) 
in PBS. For immunocytochemistry, cells were grown on a poly-L-
lysine-coated 60mm2 cover glass bottom dish for 24 hours and rinsed 
with PBS at room temperature. Then, the cells were fixed with 4% 
paraformaldehyde for 10 minutes and permeabilized in 0.1% Triton X-
100. Nonspecific binding was blocked with 1% bovine serum albumin 
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(Bovogen, East Keilor, VIC, AUS) in PBS. The fluorescent 
immunostaining was performed with the primary antibodies for p-
STAT3 (1:200; Cell Signaling Technology, MA, USA), STAT3 (1:200; 
Abcam, Cambridge, UK), Iba-1 (1:200; Wako, Japan), Iba-1 (1:200; 
Novus Biologicals, CO, USA), NeuN (1:200; Merck Millipore, MA, 
USA), and visualized using Cy3 goat anti-mouse IgG, 488 goat anti-
mouse IgG, Cy3 donkey anti-rabbit IgG (1:200; BioLegend, CA, USA), 
488 donkey anti-rabbit IgG (1:200; Abcam, Cambridge, UK) and 488 
bovine anti-goat IgG (1:200; Santa Cruz Biotechnology, CA, USA). The 
slides were mounted with 4',6-diamidino-2-phenylindole (DAPI), and 
images were collected using the LSM510 program on a confocal 
microscope (Carl Zeiss MicroImaging, Inc., München, Germany). 
 
Restraint stress procedure 
Mice were transferred to a behavior analysis test room before initiating 
chronic stress procedures. For the chronic stress, the experimental group 
was immobilized in a rodent restrainer (Ø, 30×95mm) and separated 
from the control group for the duration (2 hours a day for 14 consecutive 
days). After the chronic restraint stress, the mice were returned to their 




Behavioral experiments were performed independently according to the 
behavioral test paradigm, and separate groups were used for each 
behavioral test paradigm. Experimental mice were subjected to tail 
suspension and forced swimming tests at intervals of one day after 14 
days of chronic restraint stress to assess despair-based behavior. A 
separate cohort of mice was used to conduct sucrose preference test to 
assess reward-based behavior under normal and chronic stress 
conditions. Another group was used to assess behavior based on anxiety 
and locomotion, the following series of behavioral experiments were 
conducted at intervals of two days: handling, elevated plus maze test, 
open field test, and rotarod test. All mice were sacrificed immediately 
after the behavioral experiment, and all brain tissues of the mice used in 
the behavioral experiments under chronic restraint stress were extracted. 
 
Forced swim test 
The forced swim test was performed as described previously (Page et al, 
1999). Briefly, mice were placed in a glass beaker (2L beaker) which was 
filled to a depth of 18 cm with water (25°C). The water was regularly 
changed between subjects. The duration of immobility was recorded and 
measured with a video camera for 6 minutes. 
 
Tail suspension test 
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Mice were suspended by their tails from a steel bar using adhesive tape 
in a chamber with opaque walls. The distance between the floor of the 
chamber and the steel bar was approximately 40cm. Mice that climbed 
onto their tails or fell off during the test were excluded from analyses. 
Mice movements were videotaped for 6 minutes, and the total duration 
of immobility recorded. 
 
Sucrose preference test 
The sucrose preference test was conducted as described previously 
(Strekalova et al, 2004). After food and water deprivation for 24 hours, 
mice were given free access to both water and 1% sucrose solution in 
individual cages for 24 hours. The position of each bottle was switched 
after 12 hours to rule out side preference. The consumption of water and 
sucrose solution was measured by weighing the bottles. The preference 
for sucrose solution was calculated as a percentage of the volume of 
consumed sucrose solution over the total volume of liquid drunk. 
 
Open field test 
Mice were placed in the center of an open field box (40×40×40cm), 
illuminated by the light of 20 lx intensity and the mice movements were 
recorded with a video camera for 30 minutes. The total distance traveled 
and time spent in the center of the entire open field (20×20cm) were 
 20 
calculated using video tracking software (EthoVision XT 8.5, Noldus, 
USA). 
 
Elevated plus maze test 
The elevated plus maze consisted of two open arms (30×5cm) and two 
closed arms of the same size, with 15cm high side walls. The four arms 
and central square were 50cm above the ground. Mice were placed in 
the central square of the maze (5×5cm), facing the open arms. The mice 
movements were recorded during a 5-minutes test period. The number 
of entries, the time spent in the open and closed arms were calculated 
using video tracking software (EthoVision XT 8.5, Noldus, USA). 
 
Rotarod test 
The rotarod test was performed by a coordination test system (Rotamex 
5, Columbus Ins, USA). The mice were placed on a rotating rod (3cm in 
diameter) accelerated from 3 to 50rpm for 6 minutes. 
 
Cytokine array and enzyme-linked immunosorbent assay (ELISA) 
The expression of cytokines and chemokines in the culture supernatant 
was assessed with a mouse cytokine antibody array panel A (R&D 
Systems, MN, USA) according to the manufacturer’s instructions. Total 
M-CSF in the conditioned medium of the cultured cells was measured 
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using the quantikine ELISA kit (R&D Systems, MN, USA) according to 
the manufacturer’s instructions. The data were presented as absorbance 
units at 450 nm and correction absorbance units at 540 nm from three 
independent experiments. 
 
RNA isolation and quantitative real-time PCR 
Total RNA was isolated from BV2 and HT22 cells using an RNAiso Plus 
reagent (Takara, Shiga, Japan) and cDNA was synthesized using 
ReverTra Ace qPCR RT Master Mix (TOYOBO, Osaka, Japan). 
Quantitative real-time PCR was performed using the EvaGreen qPCR 
Mastermix (Applied Biological Materials, Richmond, Canada), and the 
results were normalized to the signals of GAPDH expression. Primers for 
CCL2 (QT00167832), STAT3 (QT00148750), ICAM-1 (QT00155078), 
TNF-α (QT00104006), IL-1β (QT01048355), IL-6 (QT00098875), 
IL-10 (QT00106169), M-CSF (QT01164324) and GAPDH 
(QT01658692) were purchased from Qiagen. 
 
Western Blot 
Cells were washed with the cold PBS, and then lysed in the triton lysis 
buffer containing 1% Triton X-100, 50mM Tris-HCl (pH 7.4), 0.35 M 
NaCl, 0.5% Nonidet P-40, 10% glycerol, 0.1% SDS, 1mM EDTA, 1mM 
EGTA, 0.2mM Na3VO4, 1mM PMSF and 0.5mM NaF. Brain tissue was 
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homogenized and lysed in the triton lysis buffer. After incubation for 30 
minutes on ice, insoluble debris was removed by centrifugation at 
16,000×g for 10 minutes at 4°C. The lysates were resolved in sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to nitrocellulose membranes (GE Healthcare, Pittsburgh, PA, 
USA). The membranes were blocked in 5% skim-milk (LPS solutions, 
Daejeon, Korea) and probed with the primary antibodies for phospho-
STAT3 (Tyr705), STAT3, phospho-ERK1/2 (Thr202 / Tyr204), ERK1/2, 
phospho-Akt (Ser473), Akt (1:1,000; Cell Signaling Technology, MA, 
USA), BDNF, phospho-GSK3β (Ser9), GSK3β (1:1,000; Santa Cruz 
Biotechnology, CA, USA), α-tubulin (1:1,000; Thermo Scientific, 
Grand Island, NY, USA), VGLUT1, PSD95 (1:2,000; 1:1,000; Synaptic 
Systems, Göttingen, Germany), Synaptophysin (1:1,000; Epitomics, 
Burlingame, CA, USA), GFAP (1:1,000; DAKO, CA, USA) and Iba-1 
(1:1,000; Novus Biologicals, CO, USA) for the target molecules, 
followed by HRP-conjugated secondary antibodies for goat anti-mouse 
IgG, goat anti-rabbit IgG (1:10,000; Enzo Life Science, NY, USA) and 
donkey anti-goat IgG (1:10,000; Santa Cruz Biotechnology, CA, USA). 
The membranes were visualized using an ECL detection kit (SurModic 
Inc., Eden Prairie, MN, USA). 
 
Slice preparation for tissue slice culture 
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Mice were anesthetized with isoflurane and decapitated, and the brains 
were immediately removed and placed in ice-cold slicing solution (0-
4°C) containing the following artificial cerebrospinal fluid (aCSF): 
124mM NaCl, 2.5mM KCl, 1mM NaH2PO4, 1.3mM MgCl2, 2.5mM 
CaCl2, 26.2mM NaHCO3, and 20mM D-glucose, bubbled with a gas 
mixture of 5% CO2 / 95% O2 to maintain a pH of 7.4. Coronal slices 
containing mPFC were obtained using a Vibratome (slice thickness 
250μm; Leica VT1200S; Leica, Nussloch, Germany). After cutting, the 
slices were kept for 30 minutes at 35°C and stimulated with M-CSF 
(10nM) for synaptosomal preparations. 
 
Golgi staining 
Dendritic spine density was analyzed using an FD Rapid GolgiStain Kit 
(FD Neurotechnologies, Baltimore, MD, USA) was used according to the 
manufacturer’s instructions. In brief, mice were anesthetized with 
isoflurane and decapitated. The brains were immediately removed, rinsed 
and immersed in the impregnation solution and stored at room 
temperature for two weeks in the dark. The brains were transferred into 
a solution containing sucrose and stored at room temperature in the dark 
for at least three days. Frozen slices of the brain were cut using a freezing 
microtome (100μm, Cryotome FE, Thermo Shandon, Runcom, UK). 
The slices were mounted on gelatin-coated microscope slides and then 
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allowed to air dry at room temperature in the dark for three days. Slides 
were then rinsed with distilled water before being dehydrated in absolute 
alcohol, cleared with xylene, and covered with non-acidic synthetic 
balsam and cover slips. 
 
Brain synaptosomal preparation 
Brain synaptosomal preparation was performed as described previously 
(Kamat et al, 2014). In brief, the prefrontal cortex was homogenized in 
10% (w/v) of 0.32M sucrose-HEPES buffer on ice, and the homogenate 
was centrifuged at 600×g for 10 minutes at 4–8°C. The HEPES buffer 
was composed of 145mM NaCl, 5mM KCl, 2mM CaCl2, 1mM MgCl2, 
5mM glucose, and 5mM HEPES (pH 7.4). The supernatant was diluted 
1:1 with 1.3M HEPES sucrose, to yield a suspension with a final 
concentration of 0.8M HEPES sucrose. This suspension was further 
centrifuged at three times with HEPES buffer at 12,000×g for 15 minutes 
at 4°C. The pellet consisting of synaptosomes was suspended in RIPA 
buffer (mixed with a protease inhibitor and PMSF) along with 0.2% 
TritonX-100 and centrifuged at 20,000×g for 30 minutes. The resulting 
synaptosomes were immediately used for the Western blot. 
 
Statistical analysis 
One-way analysis of variance (ANOVA) was used for the statistical 
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analysis of cytokine array. Multiple comparisons were investigated via 
Tukey-Kramer’s post hoc test. Two-way ANOVA (genotype × stress) 
was applied to assess behavioral experiments with chronic restraint stress. 
Bonferroni’s post hoc test was performed if applicable. Repeated 
measures ANOVA (genotype × trial session) was used to analyze 
locomotive activity and learning and memory. Group comparisons of 
immunofluorescence intensity, RNA and protein expressions were 
performed by Student’s t-tests. The data were assessed to ensure 
normality with the Shapiro-Wilk test, and where violations of the 
normality assumptions were found, non-parametric statistics were 
conducted. All data are presented in means ± standard error of means 
(SEM). All statistical analyses were conducted using SigmaPlot software 





Targeting STAT3 in microglia by using STAT3fl/fl;LysM-Cre+/- mice 
Microglia are unique glial cells derived from common myeloid 
progenitors during developmental stages of the CNS, possibly explaining 
the experimental paradigm for neuron-microglia interactions. In this 
study, I targeted STAT3 in microglia, a key transcription factor for 
immune responses, due to its relevance in the regulation of cytokine 
expression levels. I employed the myeloid cell-specific STAT3-deficient 
mouse model by breeding STAT3 floxed mice and LysM-Cre mice. I 
denoted STAT3wt/fl;LysM-Cre+/- as wild-type (WT) and 
STAT3fl/fl;LysM-Cre+/- as knockout (KO) (Figure 1a).  
 
  To verify a STAT3 depletion in microglia, STAT3 gene knockout was 
first confirmed by genotyping (Figure 1b). The absence of microglial 
STAT3 expression (red, anti-STAT3; green, anti-Iba-1) in the 
prefrontal cortex of STAT3fl/fl;LysM-Cre+/- mice was verified using 
tissue immunostaining. The profile of immunofluorescence intensity 
showed that STAT3 was not expressed in microglia (Figure 2). In primary 
cultured microglial cells (red, anti-Iba-1) obtained from the STAT3-
deficient mouse model, the expression of STAT3 (green, anti-STAT3) 
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was completely depleted in STAT3fl/fl;LysM-Cre+/- mice as well as 
shown in quantitative data (Figure 3a and b; p < 0.001). From the 
immunoblotting analysis, I also confirmed that the STAT3 expression 
was depleted specifically in microglia, but not in neurons and astrocytes 
that were isolated from each primary cultured cell (Figure 3c; p < 0.001). 
Additionally, depletion of STAT3 in microglia had no effect on the 
expression of STAT3 in neurons and on the number of both neurons and 
microglia in STAT3fl/fl;LysM-Cre+/- mice (Figure 4 and Figure 5).  
 
Loss of microglial STAT3 leads to antidepressive-like behavior 
To investigate the behavioral correlates of neuron-microglia interactions, 
I examined mood-related behaviors in the model mice. Interestingly, I 
observed antidepressive-like behaviors in the tail suspension test, forced 
swim test, sucrose preference test, and open field test. As animal models 
of stress-induced depression to validate the stress-resistant behavior, I 
induced chronic restraint stress for 2 hours a day for 2 weeks. The level 
of STAT3 phosphorylation were increased in the wild-type, but not in 
STAT3fl/fl;LysM-Cre+/- mice under chronic stress conditions (Figure 6). 
In the tail suspension and forced swim tests, the immobility time was 
significantly reduced in STAT3fl/fl;LysM-Cre+/- mice both in control and 
in chronic stress conditions (Figure 7a; genotype × stress interaction: 
F(1,38) = 1.443, p = 0.237; genotype effect: F(1,38) = 24.906, p < 0.001; 
 28 
stress effect: F(1,38) = 8.469, p = 0.006, and Figure 7b; genotype × stress 
interaction: F(1,36) = 0.415, p = 0.523; genotype effect: F(1,36) = 23.718, p 
< 0.001; stress effect: F(1,36) = 38.4, p < 0.001). Under chronic stress 
conditions, the immobility time of STAT3fl/fl;LysM-Cre+/- mice was 
increased in the forced swim tests, but not in the tail suspension tests 
(Figure 7b). These results indicate that STAT3fl/fl;LysM-Cre+/- mice had 
intrinsic resistance owing to genetic modification, and showed partial 
resilience to chronic stress conditions. To ensure consistency among 
wild-type groups, immobility time was further compared in the tail 
suspension and forced swim test. The wild-type groups did not differ 
from each other (Figure 8). Corroborating the generality of these findings, 
the wild-type mice subject to chronic restraint stress exhibited a 
significant decrease in sucrose preference. However, the sucrose 
preference of STAT3fl/fl;LysM-Cre+/- mice was higher than wild-type 
mice under chronic stress conditions (Figure 9a; genotype × stress 
interaction: F(1,35) = 12.295, p = 0.001; genotype effect: F(1,35) = 15.764, 
p < 0.001; stress effect: F(1,35) = 15.601, p < 0.001). Both wild-type and 
STAT3fl/fl;LysM-Cre+/- mice showed similar amounts of liquid intake 
under both control and stressed conditions (Figure 9b; genotype × stress 
interaction: F(1,35) = 0.573, p = 0.454; genotype effect: F(1,35) = 0.177, p = 
0.677; stress effect: F(1,35) = 4.071, p = 0.051). Lastly, I verified reduced 
locomotor activity of STAT3fl/fl;LysM-Cre+/- mice in the open field test 
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(Figure 10a; p < 0.05), but not the exploration time in the center area 
(Figure 10b). A previous study demonstrated that the stressed mice 
showed enhanced locomotor activity under the light of modest brightness 
(Strekalova et al, 2004). My results suggest that antidepressive-like 
behavior was observed in STAT3fl/fl;LysM-Cre+/- mice. Collectively, 
dysregulation of STAT3 in microglia successfully alleviated depressive 
and stress-induced behaviors. 
 
  In addition, I found no differences in body weight, anxiety-related and 
motor behaviors of STAT3fl/fl;LysM-Cre+/- mice (Figure 11; trial session 
effect: F(2,30) = 83.245, p < 0.001; genotype effect: F(1,15) = 0.008, p = 
0.931), demonstrating that deletion of STAT3 in microglia had solely 
contributed to antidepressive effects. I also tested whether the 
antidepressive effects could affect other cognitive functions associated 
with learning and memory, but found neither cognitive impairment nor 
enhancement in STAT3fl/fl;LysM-Cre+/- mice (Figure 12).  
 
Downregulation of microglial STAT3 increases neuronal M-CSF levels 
in neuron-microglia interactions 
To identify key factors affecting antidepressive-like behavior caused by 
depletion of microglial STAT3, I first examined the cytokine levels in the 
brain tissue of both wild-type and STAT3fl/fl;LysM-Cre+/- mice using a 
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cytokine array. The data showed that M-CSF was increased solely in 
STAT3fl/fl;LysM-Cre+/- mice (Figure 13; one-way ANOVA: F(1,4) = 
9.304, p < 0.05). The effect of M-CSF in association with antidepressive-
like behavior was highly localized to several brain regions, such as 
prefrontal cortex, cerebellum, and hippocampus, where M-CSF 
receptors were primarily expressed (Figure 14a; p < 0.001, b; p < 0.01, 
and c; p < 0.05). However, I could not detect any change in the levels of 
canonical cytokines, such as ICAM-1, IL-1β, TNF-α, IL-6 and IL-
10 (Figure 14 and Figure 15). These results suggest that M-CSF may be 
a key factor for regulating antidepressive-like behavior. To determine 
whether peripheral macrophages had an effect on increasing M-CSF, I 
applied the same cytokine array to peritoneal macrophages isolated from 
both wild-type and STAT3fl/fl;LysM-Cre+/- mice (Figure 16a and b). 
sICAM-1 and CCL2 were increased, but CXCL13 was decreased in 
macrophages of STAT3fl/fl;LysM-Cre+/- mice (Figure 16c; CXCL13: F(1,2) 
= 71.092, p < 0.05; sICAM-1: F(1,2) = 22.346, p < 0.05; CCL2: F(1,2) = 
71.906, p < 0.05). These factors were expressed at the similar level in the 
brain tissue, indicating that M-CSF-mediated antidepressive-like 
behavior was not associated with peripheral macrophages. In short, the 
results indicate that M-CSF production regulates antidepressive-like 
behaviors through neuron-microglia interactions.  
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  To mimic the neuron-microglia interactions of STAT3fl/fl;LysM-
Cre+/- mouse model, I performed in vitro co-culture using transwell 
inserts with both the neuronal cell line HT22 and the microglia cell line 
BV2 (Figure 17a). Endogenous STAT3 level was silenced by transfection 
with specific small interfering RNA for STAT3 (siSTAT3) in BV2 cells 
with the maintenance of cell viability (Figure 17b and c). Although the 
mRNA level of STAT3 and ICAM-1 in BV2 cells decreased in the co-
culture system, the M-CSF, IL-1β, and TNF-α levels remained 
unchanged in the cells (Figure 18a; STAT3: p < 0.001, ICAM-1: p < 
0.01). Importantly, the mRNA level of M-CSF increased in HT22 cells 
co-cultured with STAT3 knocked-down BV2 cells, but no change was 
observed in the STAT3, ICAM-1, IL-1β and TNF-α mRNA levels 
(Figure 18b; p < 0.01).  
 
  Based on the results, I hypothesized that the secretion of M-CSF may 
occur mainly in neuronal cells. To examine this, I measured the 
concentration of M-CSF using an ELISA in the co-culture system. The 
amount of secreted M-CSF was highly increased in the co-culture 
medium of HT22 cells with STAT3-silenced BV2 cells (Figure 19a; p < 
0.001); however, that of M-CSF secretion had no difference between the 
control and STAT3-silenced BV2 cells (Figure 19b). Thus, the data 
suggest that ablation of STAT3 in microglia is crucial for the increase in 
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M-CSF production in neuronal cells and that these mechanisms may 
play a crucial role in neuronal functions, leading to the antidepressive-
like behavior in STAT3fl/fl;LysM-Cre+/- mice.  
 
  In order to examine which factors from microglia could increase the 
release of M-CSF from neurons, I analyzed the cytokine/chemokine 
profiles of microglia in the STAT3-deficient mouse model. The results 
showed that the expression of CCL2 was reduced in primary microglia 
isolated from STAT3fl/fl;LysM-Cre+/- mice as well as in STAT3-silenced 
BV2 cells from in vitro co-culture system (Figure 20). I assumed that 
CCL2 in microglia contributed to the increase of M-CSF in neurons. 
However, the following results indicated that CCL2 had no effects on the 
changes of M-CSF levels in neurons (Figure 21a). Besides, the expression 
level of CCL2 had no differences between the brains of wild-type and 
STAT3fl/fl;LysM-Cre+/- mice (Figure 21b). These results indicate that 
CCL2 was not involved in the M-CSF production. 
 
M-CSF upregulates antidepressant signaling pathways and BDNF 
expression 
To identify how the secreted M-CSF triggers the activation of 
antidepressant signaling pathways, I investigated brain-derived 
neurotrophic factor (BDNF) levels and signaling cascades of ERK1/2 and 
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Akt/GSK3β in the STAT3fl/fl;LysM-Cre+/- mouse model. I observed that 
the BDNF expression as well as ERK1/2 and Akt/GSK3β 
phosphorylation was increased in several brain regions of 
STAT3fl/fl;LysM-Cre+/- mice, including the prefrontal cortex, cerebellum, 
and hippocampus (Figure 22; all p < 0.05). In synaptosomes from the 
prefrontal cortex of STAT3fl/fl;LysM-Cre+/- mice, the phosphorylation 
of ERK1/2 and Akt/GSK3β was enhanced, along with increased BDNF 
expression; however, I found no changes in the levels of pre-/post-
synaptic proteins, such as synaptophysin, VGLUT1, and PSD95 (Figure 
23; all p < 0.05). Lastly, I verified the direct effects of M-CSF on ERK1/2 
and Akt/GSK3β signaling pathways in a time-dependent manner in 
synaptosomes from cortical slices of the wild-type mice. M-CSF 
stimulation gradually increased phosphorylation of ERK1/2 and 
Akt/GSK3β in synaptic level (Figure 24; ERK1/2 at 30, 60 min, Akt and 
GSK3β at 30 min: p < 0.05, Akt at 15 min and GSK3β at 60 min: p < 
0.01). The results imply that M-CSF activates antidepressant pathways, 
along with BDNF production.  
 
I further confirmed the results in in vitro co-culture system. The 
expression of BDNF as well as phosphorylation of ERK1/2 and 
Akt/GSK3β was increased only in HT22 cells co-cultured with STAT3-
silenced BV2 cells (Figure 25; all p < 0.05). As expected, BDNF 
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expression was persistently increased, and both ERK1/2 and 
Akt/GSK3β remained phosphorylated after M-CSF stimulation for 24 
hours in HT22 cells (Figure 26; all p < 0.05). Finally, I observed the direct 
effects of M-CSF within an hour on ERK1/2 and Akt/GSK3β signaling 
pathways in HT22 cells (Figure 27; ERK1/2 at 60 min, Akt at 30 min, 
and GSK3β at 15, 30 min: p < 0.05, ERK1/2 at 15, 30 min, Akt at 15 
min, and GSK3β at 60 min: p < 0.01).  
 
However, I found no direct effects of peritoneal macrophages on 
neuronal cells. ERK1/2 and Akt/GSK3β signaling pathways did not 
induce any change in HT22 cells with macrophage cell line RAW264.7 
medium regardless of whether STAT3 was downregulated or not (Figure 
28). I reasoned that the effects of M-CSF stimulation on microglia 
should be tested since M-CSF was one of the well-known inducers for 
intracellular signaling in microglia (Imai and Kohsaka, 2002). Data 
showed that the phosphorylation of ERK1/2 and Akt/GSK3β did not 
increase in STAT3-silenced BV2 cells (Figure 29). Collectively, these data 
strongly indicate that M-CSF may be critically involved in 
antidepressive-like behavior by upregulating BDNF expression through 
a direct effect on the ERK1/2 and Akt/GSK3β signaling cascades.  
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As neuronal mechanisms of depression, the increased synaptic 
transmission could be a potent mechanism from a therapeutic point of 
view (Duman and Aghajanian, 2012a). Previous study has found that 
neuronal activation of GSK3β decreases presynaptic glutamate release 
(Wildburger and Laezza, 2012). In addition, the ERK1/2 intracellular 
pathway is a major mediator of BDNF which affects presynaptic 
neurotransmitter release rather than morphological changes of synapses 
(Hetman et al, 1999; Yu and Chen, 2011). In morphological perspectives, 
Golgi staining showed no differences in the number of dendritic spines 
between the wild-type and STAT3fl/fl;LysM-Cre+/- mice (Figure 30). 
These results imply that microglia-derived effects could facilitate the 
release of neurotransmitters on presynaptic synapses. I concluded that 
elevated M-CSF secretion in neuronal cells caused by interaction with 





Figure 1. Generation of microglia-specific STAT3 knockout mice by 
LysM gene targeting 
(a) Schematic representation of breeding strategy. The first offspring (F1) 
were obtained from a STAT3fl/fl/LysM-Cre+/+ crossing, and 
STAT3wt/fl;LysM-Cre+/- (F1) were further mated with STAT3 floxed mice. 
The second offspring (F2) were divided into four groups: 
STAT3wt/fl;LysM-Cre-/-, STAT3fl/fl;LysM-Cre-/-, STAT3wt/fl;LysM-
Cre+/- and STAT3fl/fl;LysM-Cre+/-. (b) PCR analysis of STAT3 floxed 




Figure 2. A microglia-specific deletion of STAT3 in brain tissues of 
STAT3fl/fl;LysM-Cre+/- mice 
Immunofluorescence staining for STAT3 (red), Iba-1 (green) and DAPI 
(blue) was performed in the PFC of the WT and KO mice. Scale 
bar=40µm. Scale bar of the enlarged image=10µm. The graph shows 




Figure 3. A specific deletion of STAT3 in primary microglia of 
STAT3fl/fl;LysM-Cre+/- mice 
(a) Immunocytochemistry for STAT3 (green) and Iba-1 (red) was 
performed in the primary microglia cells of the WT and KO mice. Scale 
bar = 50µm. (b) The relative immunofluorescence intensity was used to 
represent protein levels of STAT3 and Iba-1 (STAT3; 1 ± 0.058 vs 0.245 
± 0.021, Iba-1; 1 ± 0.075 vs 0.974 ± 0.054 in primary microglia of the 
WT and KO mice, n = 3 mice / group, respectively). (c) Western blot 
analysis of STAT3, Iba-1, PSD95 and GFAP in primary microglia, 
neurons, and astrocytes of the WT and KO mice. Each quantification of 
Western blot was obtained with relative densitometry and normalized 
with α-tubulin. Data are means ± SEM, and *p < 0.05, **p < 0.01, 





Figure 4. Microglia-specific STAT3 KO mice show no difference in 
STAT3 expression in neurons. 
(a) Immunofluorescence staining of NeuN (green), STAT3 (red) and 
DAPI (blue) was performed in the PFC of the WT and KO mice (Scale 
bar = 80µm, n = 3 mice/group). (b) The relative immunofluorescence 
intensity was used to represent protein levels of NeuN and STAT3 (NeuN; 





Figure 5. No difference in the number of microglia and neurons between 
the WT and KO mice 
(a) Immunofluorescence staining of Iba-1 (red), NeuN (green) and DAPI 
(blue) was performed in the PFC of the WT and KO mice (Scale bar = 
80µm). (b) Quantification of Iba-1+ cell density (61.5 ± 0.6 cells/mm2 
vs 63.7 ± 2 cells/mm2 in the WT and KO mice, n = 5 mice/group). (c) 
Quantification of NeuN+ cell density (302 ± 12 cells/mm2 vs 303.3 ± 




Figure 6. Chronic restraint stress enhances STAT3 phosphorylation in 
microglia of the WT mice. 
Immunofluorescence staining for p-STAT3 (red), Iba-1 (green) and 
DAPI (blue) was performed in the PFC of the WT and KO mice. Scale 
bar = 40µm. Scale bar of the enlarged image = 10µm. The graph shows 






Figure 7. STAT3fl/fl;LysM-Cre+/- mice exhibit antidepressive-like 
behaviors in the tail suspension and forced swim tests. 
(a) Under control or chronic restraint stress conditions, immobility time 
of the WT and KO mice was assessed by tail suspension test (Control; 
148.943 ± 9.943 sec vs 103.537 ± 13.837 sec, n = 12 and 11, Stress; 
198.208 ± 8.490 sec vs 124.013 ± 13.878 sec in the WT and KO mice, 
n = 9 and 10, respectively). (b) Under control or chronic restraint stress 
conditions, immobility time of the WT and KO mice was assessed by 
forced swim test (Control; 115.945 ± 9.695 sec vs 65.678 ± 10.593 sec, 
n = 10 and 11, Stress; 197.328 ± 9.733 sec vs 131.727 ± 16.008 sec in 
the WT and KO mice, n = 9 and 10, respectively). Data are means ± 
SEM, *p < 0.05, **p < 0.01, ***p < 0.001 compared with WT; #p < 




Figure 8. Wild-type groups are not different in the tail suspension and 
forced swim tests. 
(a) Immobility time of four distinct groups was assessed by tail 
suspension test (STAT3wt/fl;LysM-Cre-/-; 143.87 ± 12.764 sec, 
STAT3fl/fl;LysM-Cre-/-; 155.409 ± 19.913 sec, STAT3wt/fl;LysM-Cre+/-; 
148.943 ± 9.943 sec, STAT3fl/fl;LysM-Cre+/-; 103.537 ± 13.837 sec, n 
= 10, 12, 12 and 11, respectively) and (b) forced swim test 
(STAT3wt/fl;LysM-Cre-/-; 130.136 ± 10.86 sec, STAT3fl/fl;LysM-Cre-/-; 
136.256 ± 13.112 sec, STAT3wt/fl;LysM-Cre+/-; 115.945 ± 9.695 sec, 
STAT3fl/fl;LysM-Cre+/-; 65.678 ± 19.593 sec, n = 11, 12, 10 and 11, 






Figure 9. STAT3fl/fl;LysM-Cre+/- mice show antidepressive-like 
behaviors in the sucrose preference. 
(a) Preference for sucrose under control or chronic restraint stress 
conditions (Control; 75.776 ± 1.914 % vs 77.061 ± 1.943%, Stress; 
55.13 ± 4.146 % vs 75.833 ± 2.341 % in the WT and KO mice, n = 10 
and 9, respectively). (b) Total liquid intake under control or chronic 
restraint stress conditions (Control; 4.91 ± 0.119 ml vs 4.95 ± 0.092 ml, 
Stress; 5.24 ± 0.121 ml vs 5.1 ± 0.097 ml in the WT and KO mice, n = 
10 and 9, respectively). Data are means ± SEM, *p < 0.05, **p < 0.01, 
***p < 0.001 compared with WT; #p < 0.05, ##p < 0.01, ###p < 0.001 




Figure 10. STAT3fl/fl;LysM-Cre+/- mice does not show anxiety in the 
open field tests, but exhibits antidepressive-like behaviors. 
(a) Total distance (11794.746 ± 811.651 cm vs 9267.810 ± 819.674 cm 
in the WT and KO mice) and (b) time spent in the center of the open 
field (160.3 ± 19.6 sec vs 168.9 ± 34 sec in the WT and KO mice, n = 
8 and 9, respectively). Data are means ± SEM, *p < 0.05, **p < 0.01, 





Figure 11. No difference in body weight, anxiety, and locomotor function 
between the WT and KO mice 
(a) Body weight of male mice aged 8 weeks (21.7 ± 0.4 g vs 21.2 ± 1 g 
in the WT and KO mice, n = 10 and 7, respectively). (b) Time spent in 
the open arms of plus arms (133.6 ± 17.5 sec vs 150.4 ± 30.2 sec in the 
WT and KO mice, n = 8 and 9, respectively). (c) Total running time on 





Figure 12. No difference in cognitive function between the WT and KO 
mice 
(a) Morris water maze test was performed for 7 consecutive days, and 
the escape latency was measured (n = 11 and 14). The repeated two-
way ANOVA test indicated a significant main effect of training sessions 
(F(6,192) = 15.679; p < 0.001) but a main effect of genotype (F(1,32) = 
4.095; p = 0.051). (b) The quadrant occupancy, (c) the velocity (18.2 ± 
1.1 cm/s vs 20.2 ± 0.9 cm/s in the WT and KO mice, respectively), (d) 
the number of crossing (1.46 ± 0.41 vs 1.64 ± 0.39 in the WT and KO 
mice, respectively), and (e) the total traveled distance (1092.1 ± 67.9 cm 
vs 1212.4 ± 54.8 cm in the WT and KO mice, respectively) of the probe 




Figure 13. Detection of multiple cytokines in the whole brain tissues of 
the WT and KO mice 
(a) Expression of cytokines and chemokines in the whole brain tissues of 
the WT and KO mice using cytokine arrays. (b) The bar graph was 
calculated for each cytokine with mean pixel density. Representative data 




Figure 14. mRNA levels of canonical cytokines in various brain regions 
(a) Relative mRNA levels of M-CSF, ICAM-1, IL-1β and TNF-α in 
the prefrontal cortex, (b) cerebellum and (c) hippocampus. 




Figure 15. mRNA levels of STAT3 target genes in the whole brain of the 
WT and KO mice 
Relative mRNA levels of IL-6 and IL-10 were quantified by qRT-PCR 
(IL-6; 1.003 ± 0.058 vs 0.957 ± 0.061, IL-10; 1.003 ± 0.056 vs 0.903 





Figure 16. Detection of multiple cytokines in peripheral macrophages of 
the WT and KO mice  
(a) Western blot analysis of STAT3 in peritoneal macrophages isolated 
from the WT and KO mice. (b) Expression of cytokines and chemokines 
in the peritoneal macrophages of the WT and KO mice using cytokine 
arrays. (c) The bar graph was calculated for each cytokine with men pixel 
density. Each quantification of Western blot was obtained with relative 
densitometry and normalized with α-tubulin. Data are means ± SEM, 
and *p < 0.05, **p < 0.01, ***p < 0.001. Representative data from three 




Figure 17. Interactions between neurons and microglia using in vitro co-
culture system 
(a) Schematic representation of the co-culture system between BV2 and 
HT22 cells. (b) Western blot analysis of STAT3 and (c) cell viability (100 
± 11 % vs 94.636 ± 10.4 % in scrambled and siSTAT3, n = 3/group, 
respectively) in BV2 cells after scrambled or STAT3 siRNAs transfection. 
Each quantification of Western blot was obtained with relative 
densitometry and normalized with α-tubulin. Data are means ± SEM, 
and *p < 0.05, **p < 0.01, ***p < 0.001. Representative data from three 





Figure 18. Effects of STAT3-deficient microglia on neuronal M-CSF 
production in neuron-microglia interactions 
(a) Relative mRNA levels of STAT3, M-CSF, ICAM-1, IL-1β and 
TNF-α in BV2 cells and (b) HT22 cells from the co-culture system was 
quantified by qRT-PCR. Each quantification of Western blot was 
obtained with relative densitometry and normalized with α-tubulin. 
Data are means ± SEM, and *p < 0.05, **p < 0.01, ***p < 0.001. 




Figure 19. Increased M-CSF secretion in neurons by STAT3-deficient 
microglia 
(a) Concentration of M-CSF from the co-cultured medium (217 ± 
3.4pg/ml vs 300 ± 9pg/ml, n = 8/group, respectively) and (b) the BV2-
cultured medium (29.2 ± 2.6pg/ml vs 26.7 ± 2.2pg/ml, n = 3/group, 
respectively) were determined by ELISA. Data are means ± SEM, and 




Figure 20. Detection of multiple cytokines in the primary microglia of the 
WT and KO mice 
(a) Expression of cytokines and chemokines in the cultured medium of 
primary microglia isolated from the WT and KO mice was determined 
using cytokine arrays. (b) Bar graph was calculated for each cytokine 
with mean pixel density. (c) Relative mRNA level of BV2 cells-
transfected with either scrambled or siSTAT3 was quantified by qRT-
PCR with primers for STAT3 and CCL2 (STAT3; 1.002 ± 0.04 vs 0.447 
± 0.027, CCL2; 1.004 ± 0.06 vs 0.567 ± 0.017 in scrambled and 
siSTAT3, n = 3/group, respectively). Data are means ± SEM, and *p < 
0.05, **p < 0.01, ***p < 0.001. Representative data from three 
independent experiments are shown. 
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Figure 21. CCL2 does not influence M-CSF expression in neurons. 
(a) Relative mRNA level of M-CSF in HT22 cells after CCL2 (100ng/ml) 
stimulation for 24 hours (1.004 ± 0.064 vs 1.054 ± 0.047 in the control 
and CCL2 groups, n = 3/group, respectively). (b) Expression of CCL2 in 
the whole brain of the WT and KO mice using cytokine arrays (1.005 ± 
0.061 vs 1.027 ± 0.055 in the WT and KO mice, n = 3/group, 





Figure 22. Antidepressant signaling pathways are significantly activated 
in the brain of STAT3fl/fl;LysM-Cre+/- mice. 
(a) Western blot analysis of BDNF, ERK1/2, Akt and GSK3β in the 
prefrontal cortex (ctx), cerebellum (ceb) and hippocampus (hip) of the 
WT and KO mice. (b) Quantification of Western blot was obtained with 
relative densitometry and normalized with α-tubulin. Data are means 
± SEM, and *p < 0.05, **p < 0.01, ***p < 0.001. Representative data 




Figure 23. Activated antidepressant signaling pathways are observed in 
the synaptosomes from STAT3fl/fl;LysM-Cre+/- mice 
(a) Western blot analysis of BDNF, ERK1/2, Akt, GSK3β, 
synaptophysin, PSD95, VGLUT1, GFAP and Iba-1 in the synaptosomes 
isolated from the PFC of the WT and KO mice. (b) Quantification of 
Western blot was obtained with relative densitometry and normalized 
with α-tubulin. Data are means ± SEM, and *p < 0.05, **p < 0.01, 





Figure 24. M-CSF enhances the activation of antidepressant signaling 
pathways in the brain of STAT3fl/fl;LysM-Cre+/- mice. 
(a) Western blot analysis of ERK1/2, Akt, GSK3β, synaptophysin, 
PSD95, VGLUT1, GFAP and Iba-1 in the synaptosomes isolated from 
PFC slices of the WT mice after a time-dependent M-CSF stimulation 
(10 nM). (b) Quantification of Western blot was obtained with relative 
densitometry and normalized with α-tubulin. Data are means ± SEM, 
and *p < 0.05, **p < 0.01, ***p < 0.001. Representative data from three 





Figure 25. Neuronal M-CSF by interaction with STAT3-deficient 
microglia triggers the activation of antidepressant signaling pathways. 
(a) Western blot analysis of BDNF, ERK1/2, Akt and GSK3β in BV2 
and HT22 cells from the co-culture set. (b) Quantification of Western 
blot was obtained with relative densitometry and normalized with α-
tubulin. Data are means ± SEM, and *p < 0.05, **p < 0.01, ***p < 





Figure 26. M-CSF activates antidepressant signaling pathways in 
neuronal cell line. 
(a) Western blot analysis of BDNF, ERK1/2, Akt and GSK3β in HT22 
cells after M-CSF stimulation (40ng/ml) for 24 hours. (b) Quantification 
of Western blot was obtained with relative densitometry and normalized 
with α-tubulin. Data are means ± SEM, and *p < 0.05, **p < 0.01, 





Figure 27. M-CSF activates antidepressant signaling pathways in 
neuronal cell line. 
(a) Western blot analysis of ERK1/2, Akt and GSK3β in HT22 cells after 
a time-dependent M-CSF (40ng/ml) stimulation. (b) Quantification of 
Western blot was obtained with relative densitometry and normalized 
with α-tubulin. Data are means ± SEM, and *p < 0.05, **p < 0.01, 






Figure 28. Peripheral macrophages have no effect on antidepressant 
signaling pathways. 
(a) Schematic representation of RAW264.7 cultured medium treatments 
to HT22 cells. (b) Western blot analysis of STAT3 in RAW264.7 cells 
after scrambled or STAT3 siRNAs transfection. (c) Western blot analysis 
of BDNF, ERK1/2, Akt and GSK3β in HT22 cells treated with 
RAW264.7 cultured medium with or without STAT3 inhibition. Each 
quantification of Western blot was obtained with relative densitometry 
and normalized with α-tubulin. Data are means ± SEM, and *p < 0.05, 
**p < 0.01, ***p < 0.001. Representative data from three independent 




Figure 29. M-CSF has no effect on STAT3-silenced BV2 cells. 
Western blot analysis of STAT3, ERK1/2, Akt and GSK3β in BV2 cells 
after M-CSF (40ng/ml) stimulation for 24 hours with or without 
inhibition of STAT3 expression. Quantification of Western blot was 
obtained with relative densitometry, and normalized with α-tubulin. 
Data are means ± SEM, and *p < 0.05, **p < 0.01, ***p < 0.001. 




Figure 30. No differences in the number of dendritic spines between the 
WT and KO mice 
(a) Representative images of Golgi staining in the WT and KO groups (n 
= 5 mice/group). (b) Quantitative data for the number of dendritic spines 
(0.543 ± 0.022µm vs 0.556 ± 0.015µm in the WT and KO mice, n = 17 
and 23 neurons/group, respectively). Scale bar = 40µm. Scale bar of the 





Figure 31. Dysfunction of STAT3 in microglia enhances M-CSF action 
on neural functions, and consequently alleviates depression-related 
behaviors. 
Depicted is a schematic model explaining how microglial STAT3 could 
mediate antidepressant signaling pathways and antidepressive-like 
behavior in mice. In this model, depletion of STAT3 in microglia initiates 
its signaling through interacting with neurons, which triggers M-CSF 
production, leading to the activation of ERK1/2 and Akt/GSK3β 
through phosphorylation. Enhanced antidepressant signaling pathways 
and BDNF expression increase neurotransmitter release. Altered synaptic 
activity could contribute to the modulation of antidepressive-like 




In the present study, I explored the mechanisms of neuron-microglia 
interactions. Primarily, I used a microglia-targeted STAT3-deficient 
mouse model. From an immunological perspective, STAT3 signaling 
plays a major role in immune responses, and microglia are CNS-resident 
immune cells that sense stress in the microenvironment. However, 
microglia were shown to modulate synaptic activity through functional 
changes (Wake et al, 2013). In the current study, I demonstrated that 
dysfunction of STAT3 in microglia enhanced M-CSF action on neural 
functions along with upregulation of BDNF expression through 
antidepressant pathways, and consequently alleviated depression-related 
behaviors (Figure 31). These findings could aid in the development of 
novel pharmaceutical antidepressant drugs. 
 
My findings on the behavioral association of neuron-microglia 
interactions show that the STAT3 pathway in microglia may be strongly 
associated with antidepressive-like behavior. These behavioral 
experimental results could be categorized as the positive valence system 
according to Research Domain Criteria (RDoC) for emotional behavior. 
Despair-based behavior represented by tail suspension and forced swim 
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tests was responsible for willingness to overcome stressful responses, by 
measuring motility. Similarly, behavioral processes related to hedonic 
responses were examined in the sucrose preference test for probing the 
neural systems for reward seeking behavior. Each experimental design 
may demonstrate partial aspects of depressive symptoms mimicking 
human patients’ behavior; however, it is quite plausible for newly built 
criteria on human mental researches. 
 
For many decades, accumulating evidence has reported a positive 
relationship between depression and cytokines and/or chemokines, such 
as TNF-α, IL-1, IL-6 and the CC chemokine ligand (CCL) family 
(Khairova et al, 2009). A recent study suggested that manipulation of the 
microglia activation status with microglial stimulators, such as 
lipopolysaccharide (LPS) and M-CSF, could be a potent etiological 
therapeutics for depression symptomatology (Kreisel et al, 2014). For 
example, M-CSF could reduce the depressive-like behavior by activating 
microglia status under chronic stress conditions. In microglial STAT3-
deficient model, the microglial STAT3 as a sensor of the cytokine profiles 
was effectively depleted. Notably, the expression of M-CSF was 
increased in the brains of STAT3fl/fl;LysM-Cre+/- mice. The elevated 
mRNA levels and the secretion of M-CSF were detected in neuronal cells 
in in vitro co-culture system. These results implied the novel actions of 
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M-CSF in the absence of microglial STAT3. Under altered circumstances 
by deletion of microglial STAT3, M-CSF can be synthesized in neuronal 
cells and at the same time affect the neuronal cells themselves. For 
example, M-CSF is produced with an autocrine/paracrine mechanism 
of action in distinct brain regions, including the dorsal forebrain and 
cerebellum, and plays an essential role in neural progenitor cell 
maintenance and maturation (Chitu et al, 2016). In this study, I suggest 
that M-CSF is involved in autocrine loops in neuronal cells. 
 
Based on these results, I hypothesized that M-CSF actions in 
neuronal cells could activate certain signaling pathways for 
antidepressant drugs. In relation to BDNF signaling, I first verified that 
BDNF expression as well as the phosphorylation of ERK1/2 and 
Akt/GSK3β was increased in neuronal cells both in STAT3fl/fl;LysM-
Cre+/- mice and in in vitro co-culture system in response to secreted M-
CSF. Many studies showed that the ERK1/2 and Akt/GSK3β signaling 
subsequently induce BDNF expression (Jope et al, 2006; Obata et al, 
2003). M-CSF-induced ERK1/2 and Akt/GSK3β signaling pathways 
potentially work as the molecular mechanisms to regulate 
antidepressive-like behaviors. Shared with the mechanisms of 
conventional antidepressant drugs, my findings could be helpful to take 
less risk for developing novel therapeutics. Thus, these results indicate 
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that the regulation of ERK1/2 and Akt/GSK3β signaling pathways by 
M-CSF can be a strong candidate for the development of antidepressants. 
 
Although these results demonstrate the effects of M-CSF on the 
antidepressant signaling and behavior, further studies are needed to block 
or inhibit M-CSF signaling in STAT3fl/fl;LysM-Cre+/- mice for more 
clarification. For example, the effect of neutralizing antibodies against 
M-CSF and blocking anti-mouse M-CSF receptor (known as CSF1R) 
antibody in vivo can be verified using the chronic restrain stress model 
of STAT3fl/fl;LysM-Cre+/- mice. In addition, transgene expression can be 
restricted to certain cell types using the promoter controlling gene 
expression in the lentiviral system. Promoters providing specific 
expression in all neurons include synapsin I (SynI) and neuron specific 
enolase (NSE). Calcium/calmodulin-dependent protein kinase II alpha 
(CaMKIIα) also restricts expression to excitatory glutamatergic neurons 
(Parr-Brownlie et al, 2015). Therefore, the induction of depression in 
STAT3fl/fl;LysM-Cre+/- mice using a lentiviral shRNA vector for M-CSF 
specifically expressed in neurons can effectively demonstrate the 
relevance of antidepressant signaling pathway. 
 
The data of behavioral analysis showed that microglia-specific 
STAT3 KO mice had antidepressive-like behavior in both normal and 
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chronic restraint conditions. This result in normal conditions may be due 
to changes in the developmental stage of the brain caused by the genetic 
background of the mouse model. In addition, studies have shown that 
even without symptoms of depression, antidepressants can be effective in 
the treatment of depression. For this reason, I have focused on changes 
in protein expression under normal conditions and have addressed 
molecular mechanisms. However, in order to understand the more 
comprehensive function of the microglial STAT3 in depression, it is 
necessary to identify the molecular mechanism under chronic stress 
conditions. A recent study showed the quantitative changes of mRNAs 
in the nucleus accumbens from control, chronic unpredictable mild stress 
(CUMS)-MDD, and CUMS-resilience mice by high-throughput 
sequencings (Si et al, 2018). The data implicated that the impairment of 
dopaminergic synapse, circadian process, and calcium signaling may be 
involved in CUMS-induced depression, whereas the upregulation of 
tyrosine metabolism, cytokine-cytokine receptor interaction, and 
calcium signaling may be involved in mouse resilience to the CUMS. 
 
When it comes to neuron-microglia cross-talk, cell-to-cell 
interactions play a pivotal role in intercellular communication. For 
example, CX3CR1/CX3CL1 signaling between microglia and neurons is 
involved in synaptic engulfment, resulted in synaptic elimination (Ueno 
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et al, 2013; Zhan et al, 2014), and in the modulation of cytokine 
production and glutamatergic neurotransmission (Rogers et al, 2011; 
Scianni et al, 2013). CD200 and its receptor, CD200 receptor (CD200R), 
also have critical roles in the interplay between neurons and microglia by 
controlling anti-inflammatory signaling and by maintaining them in a 
resting state (Hoek et al, 2000). Presumably, however, my data indicated 
that de novo mechanisms of neuron-microglia cross-talk would exist. 
Ablation of STAT3 in microglia did not alter the number of synaptic 
dendritic spines. The cytokine array and ELISA experiments also 
provided that M-CSF production occurs in neuronal cells but not IL-
1β, TNF-α, IL-6, and IL-10. 
 
In undertaking this study, I initially hoped to discover unknown 
targets for neuron-microglia interactions, and investigated the target of 
microglial STAT3, which increases neuronal M-CSF from the cytokine 
array. As a target protein of microglial STAT3, CCL2 was treated with 
neurons to confirm the association with neuronal M-CSF production, 
but no correlation was found (Figure 18). In fact, it is necessary to 
neutralize CCL2 to determine the effect on CCL2 reduction and neuronal 
M-CSF increase for more clear identification. Despite these efforts, there 
is a limitation in studying the mechanism of interactions between 
microglia and neurons. One of the major drawbacks of cytokine array in 
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identifying unknown targets is that only a limited number of proteins can 
be analyzed. The following methods can be suggested to overcome this. 
Whole transcriptome sequencing involves large-scale monitoring of 
relative differences in RNA abundance between experimental groups, 
which can be used primarily to indicate functional changes. This 
approach has already gained insights into mechanisms of diseases and 
biological function, including neuropsychiatric disorders. I also suggest 
that systematic proteomic analysis can be an alternative approach. A 
previous study demonstrate that microglial activation occurs the dynamic 
alteration of the whole cell proteome and secretome. Numerous proteins 
involved in the immune inflammatory response and metabolism change 
dynamically as cells are exposed to inflammatory molecules (Woo et al, 
2017). Analysis of system biology, such as genomics, proteomics, and 
bioinformatics, will help to broaden understanding of dynamic and 
complex biological components that are difficult to predict. 
 
As a novel antidepressant mechanism, rapid responses mainly occur 
through receptor-mediated glutamatergic neurotransmission (Duman et 
al, 2012b). As previously mentioned, I determined the increase of 
ERK1/2 and Akt/GSK3β phosphorylation by stimulation of M-CSF. 
Regarding the ERK1/2 signaling pathways, the release of 
neurotransmitter was decreased in the inhibition of phosphorylated 
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ERK1/2 (Kushner et al, 2005). In relation to Akt/GSK3β signaling, the 
major physiological mechanism that regulates the activity of GSK3 is 
phosphorylation of GSK3 (Ser9-GSK3β). This serine phosphorylation 
inhibits the activity of GSK3 and can be catalyzed by Akt (Richard and 
Myoung-Sun, 2006). Neuronal activation of GSK3β decreases 
presynaptic glutamate release following high-frequency stimulation and 
diminishes the expression of SynI, another critical component of the 
soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) 
receptor (SNARE) complex that regulates synaptic vesicle mobilization 
(Wildburger et al, 2012). The GSK3 signaling pathway controls 
presynaptic transmitter release exerting an overall suppressive effect on 
synaptic vesicle fusion and neurotransmitter release. Thus, theses 
evidences implicated that M-CSF-induced ERK1/2 and Akt/GSK3β 
signaling could enhance the release probability of neurotransmitters, and 
help elucidate novel antidepressant mechanisms for a rapid-acting 
antidepressant response. 
 
In conclusion, microglial STAT3 was essential for promoting M-CSF 
actions on synaptic transmission, which led to antidepressive-like 
behavior. I propose that ERK1/2 and Akt/GSK3β signaling pathways 
are involved in BDNF-dependent antidepressant behaviors via M-CSF 
secretion in neuronal cells. These findings may provide a novel 
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미세아교세포는 중추신경계에 존재하는 신경아교세포계의 한 종류로 
뇌와 척수의 신경기능을 보조하거나 보호하는 기능을 한다. 특히, 
신경-미세아교세포의 상호작용은 신경-면역계를 정상적으로 유지하는 
대표적인 기전 중 하나로 알려져 있으며, 미아교세포의 활성화 상태를 
조절하는 것은 신경-면역계의 균형을 유지하는데 매우 중요하다. 
신경-면역계의 불균형은 곧 알츠하이머병, 파킨슨병, 주요우울장애 등 
여러 신경정신질환의 원인이 되기도 한다. 하지만 신경-미세아교세포의 
상호작용이 이러한 신경정신질환에서 어떤 기능을 하는지는 알려져 
있지 않다. 신호변환 및 전사활성인자 3 (STAT3)는 일반적으로 
면역세포에서 다양한 사이토카인과 성장인자들에 의해 발현되고, 세포 
활성화를 일으켜 염증성반응을 일으키는 역할을 유전자이다. 이 
연구에서는 미세아교세포-특이적 STAT3 결손이 주요우울장애같은 
신경정신질환에서 신경-미세아교세포의 상호작용을 통해 신경면역계의 
균형을 유지하고 증상을 완화시킬 것이라는 가설을 세워 연구를 
진행했다. 먼저, 미세아교세포-특이적 STAT3 결손 (STAT3fl/fl;LysM-
Cre+/-) 마우스 모델 제작하여 미세아교세포의 STAT3 유전자 활성을 
억제시켰고, 장기간의 스트레스로 우울증을 유도한 후 행동분석실험인 
강제 수영, 꼬리 매달리기, 자당 선호 및 오픈 필드 테스트를 수행하여 
항우울 유사 행동을 보임을 확인했다. 흥미로운 점은 STAT3가 결손된 
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미세아교세포가 주변의 신경세포와 상호작용을 하여 신경세포로부터 
대식세포 콜로니-자극인자 (M-CSF)의 분비를 증가시켰다는 것이다. 
상호작용을 한 신경세포는 M-CSF를 자가분비하여 항우울 
신호전달경로로 알려진 ERK1/2, Akt/GSK3β가 활성화 되었고, 뇌-
유래 신경성장인자 (BDNF) 발현이 증가되었다. ERK1/2, Akt/GSK3β 
의 활성화와 BDNF 단백질의 신경세포에서의 기능은 신경전달물질의 
방출을 증가시키는 것으로 잘 알려져 있으며, 이는 곧 마우스 모델에서 
보여준 항우울 유사 행동을 설명할 수 있는 근거가 된다. 결론적으로, 
미세아교세포 STAT3의 기능 장애는 M-CSF에 의해 매개된 신경세포 
활성을 통해 우울증 관련 행동을 조절하며, 미세아교세포 특이적인 
STAT3 기능 억제는 기존의 우울증 치료가 갖고있는 한계점을 극복 할 
수 있는 새로운 치료 전략이 될 수 있음을 시사한다. 
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